UK tech startup, Molecular Warehouse, received funding of £250,000 for a project for a molecular bio-sensing platform that can remotely monitor the levels of drugs needed to prevent organ rejection. The project opens markets for companies investing in bio-sensing technologies.
The Guildford-based company, was singled out from more than 100 contenders as the best candidate for Series A funding. The company’s application areas, which are at various stages of development, include: diagnosis of acute pancreatitis, haemophilia and coagulation, chronic stress, vitamin D deficiency and prostate cancer. At Health 2.0, a recent conference…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
